Swiss HLG Basel Networking Event

The next frontiers in Brain Health

Few indications have experienced as much innovation over that past years as Brain Health.

Doors open at 5.30pm

• Registration and Welcome coffee
• Welcome from Swiss HLG
• The new Age of CNS – latest trends and deals in Brain Health - Nathanaëlle Cellier-Fontages and Anna Exenberger, IQVIA 
• Brian McCabe, EPFL Brain Mind Institute 
• Paving the way towards new treatment paradigms in Alzheimer's and beyond - Breakthroughs in Diagnosis and Brain Delivery- Elisabeth Aloy, Roche Diagnostics and Roberto Villaseñor Solorio, Roche Pharmaceuticals
• Panel on Neuroscience Partnering  - Celine Bouquet, Roche Partnering, Richard Porter, Scientific Officer at uniQure, Beppe Cangelosi from Takeda and additional panellists to be announced shortly 
• Networking and Apero

Speaker Bios

Anna Exenberger, PhD is an Associate Principal in the Integrated Digital Health CoE embedded in IQVIA’s Commercial Strategy Consulting team, with a strong scientific background and proven track record of driving innovation in healthcare and life sciences. Anna focuses on opportunity identification and evaluation of innovative tools and technologies, with a particular interest in CNS. Prior to joining IQVIA, Anna completed a PhD in speech neuroscience, examining speech processing in the brain and changes associated with hearing impairment.

Nathanaëlle Cellier-Fontanges has 18 years of life sciences consulting and industry experience, spearheads next-generation patient engagement offerings while contributing to neuroscience-driven initiatives. Brings expertise in translating advances in neurobiology and cognitive science into strategic solutions for pharmaceutical and biotech organizations.Neuroscience Experience: Advises on strategies for neurological and neuropsychiatric portfolios, leveraging insights from brain health research, biomarkers, and emerging digital neurotechnologies to inform clinical development and market access.

Celine Bouquet is the BD Head of Neuroscience, Ophthalmology and Rare Diseases, Basel at Roche. Celine oversees the partnering transactions in these therapeutic areas and works closely with Roche’s internal research and development organization to identify opportunities that shape the Roche portfolio. She brings knowledge and experience from having led deals herself in various therapeutic areas while in Roche Pharma Partnering as well as her prior role, where she was overseeing portfolio prioritization, strategy setting and external alliances in the R&D organization from early discovery to Ph2. Celine joined Roche in 2012 and was heading the “Institut Roche”, dedicated to developing collaborative projects with academic partners to accelerate the transfer of basic research discoveries into innovative therapies in France. Prior to joining Roche, Celine gained experience and network across biotech, academia and tech transfer.An Ecole Normale Superieure de Lyon fellow, Celine holds a PhD in neuroscience from University Paris 6 and did her postdoctoral training in neuro-ophthalmology at UCSF.

Elisabeth Aloy, PhD, is the Head of Strategy at Roche Diagnostics. She has a dual background as a neuroscientist and a business leader in strategy, accelerating portfolio development and maximizing commercial value. She also has nearly two decades of strategy consulting experience, serving as a strategy consulting partner at Monitor Deloitte and leading the CNS and Rare Disease EMEA consulting practice at IQVIA.

Roberto Villaseñor is a Principal Scientist in pRED, where he leads the Brain Delivery group within the Neuroscience discovery and translational area. Roberto obtained his PhD from the Max Planck Institute for Cell Biology and Genetics in Dresden, with a background in Cell Biology. In 2014, he joined Roche to work on the Brainshuttle™ platform where he pioneered the study of the cellular mechanisms for transport across the blood-brain barrier. He has since taken on roles of increasing responsibility in the areas of blood-brain barrier biology, ADME of biologics, human in vitro model systems, and Neuroscience drug discovery. Currently, he leads the cross-functional preclinical Brainshuttle platform in Neuroscience and champions the development of novel therapeutic agents to treat Alzheimer's disease.

afficher moins